Compass Pathways Inc. saw its shares tick up in early trading, rising 1.5% to $13.19 ahead of the market open after the company reported that its experimental depression treatment showed a durable benefit six months after testing in a late-stage clinical trial.
The company said it has begun a rolling submission for marketing approval and remains on track to complete the final submission in the fourth quarter. If approved, Compass anticipates bringing the therapy, marketed as COMP360, to market in the first half of 2027, subject to a decision by the U.S. Food and Drug Administration.
Investor confidence also received a lift from actions by institutional analysts. Wells Fargo kept an Equal Weight rating on the stock but raised its price target to $12 from $9, signaling greater near-term valuation support without moving to a fully bullish stance. That adjustment provided a fresh catalyst for a name that had already been trading with notable momentum.
The price-target revision comes after a pronounced recovery from the stock's 52-week low of $6.15, with the share price more than doubling since that trough. The rebound was underpinned in part by a standout first-quarter 2026 earnings result in which Compass reported a positive earnings-per-share surprise, posting $0.03 per share compared with analyst expectations of -$0.19. That performance materially recalibrated market expectations for the residential real estate platform portion of the business.
Market participants are now watching the company's next quarterly report, which is expected in early August, to assess whether the recent momentum can be sustained.
The broader U.S. equity environment this session offered additional support for the stock's move, with the S&P 500 up 0.7%, the Nasdaq climbing 1.1% and the Dow Jones Industrial Average advancing 0.3%. Real estate technology peers also benefited from improving sentiment around housing-market conditions, with inventory levels noted as being at multi-year highs.
With shares trading near the 52-week high of $13.955, investors appear to be weighing whether the combination of an analyst re-rating and improving operational cues can push Compass to fresh highs ahead of its upcoming earnings release.
Key developments:
- Compass shares rose 1.5% in pre-market trading to $13.19 after positive late-stage trial durability data for COMP360.
- Rolling FDA submission is under way, with final submission targeted for completion in the fourth quarter; potential launch expected in H1 2027 if approved.
- Wells Fargo kept an Equal Weight rating but raised its price target to $12 from $9, adding institutional validation to the stock's momentum.
Context and next steps:
- The stock has more than doubled from its 52-week low of $6.15, helped by a Q1 2026 EPS beat of $0.03 versus estimates of -$0.19.
- Investors will monitor the early August quarterly report for signs the recent performance trend can be maintained.
- Broader market gains and improving housing sentiment are providing a favorable backdrop for real estate technology stocks.